1.Persistent α-Fetoprotein Elevation in Healthy Adults and Mutational Analysis of α-Fetoprotein Promoter, Enhancer, and Silencer Regions.
Yejoo JEON ; Yun Suk CHOI ; Eun Sun JANG ; Jin Wook KIM ; Sook Hyang JEONG
Gut and Liver 2017;11(1):136-141
BACKGROUND/AIMS: α-Fetoprotein (AFP) is normally <10 ng/mL in adults without malignancy or liver regeneration. However, hereditary or nonhereditary persistence of AFP in healthy adults may be encountered in clinical practice. This study describes four cases of persistent AFP elevation in healthy adults and investigates mutations in key transcription regulatory regions of the AFP gene as potential drivers of AFP overexpression. METHODS: Four healthy adults with persistently elevated AFP levels (12.1 to 186.1 ng/mL) for >1 year, and 20 controls with low AFP levels (<0.61 to 2.9 ng/mL) were included in the study. AFP levels were collected from the families of two of the patients. We sequenced five regions that are critical for AFP expression: a promoter, two enhancers, and two silencers. RESULTS: One of the two cases in which family information was represented is the first case of hereditary persistence of AFP in South Korea. Mutations related to AFP overexpression were not found in the transcription regulatory regions among the four patients. CONCLUSIONS: Persistent AFP elevation is a heterogeneous condition with or without a hereditary pattern and may be caused by factors outside of transcription regulatory region changes. Further research on the mechanism of AFP elevation is needed.
Adult*
;
alpha-Fetoproteins
;
Biomarkers
;
DNA Mutational Analysis
;
Humans
;
Korea
;
Liver Regeneration
;
Regulatory Sequences, Nucleic Acid
2.Development and Evaluation of a Laboratory Information System-Based Auto-Dilution and Manual Dilution Algorithm for Alpha-Fetoprotein Assay.
Tae Dong JEONG ; So Young KIM ; Woochang LEE ; Sail CHUN ; Won Ki MIN
Annals of Laboratory Medicine 2013;33(5):390-392
No abstract available.
*Algorithms
;
Automation
;
Clinical Laboratory Information Systems/*standards
;
Humans
;
Immunoassay/*methods
;
Indicator Dilution Techniques
;
alpha-Fetoproteins/*analysis
4.General therapy of pediatric malignant germinoma: experience of 7 cases.
Wei-Ling ZHANG ; Yi ZHANG ; Dong-Sheng HUANG ; Liang HONG ; Yi-Zhuo WANG ; Ai-Ping LIU ; Jing LI ; Yan ZHOU
Chinese Journal of Contemporary Pediatrics 2011;13(2):163-164
Child
;
Child, Preschool
;
Combined Modality Therapy
;
Female
;
Germinoma
;
blood
;
therapy
;
Humans
;
Infant
;
Male
;
alpha-Fetoproteins
;
analysis
5.Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma
Gehan Abd Elatti KHEDR ; Sherif Farouk ELZAWAWY ; Ahmad Gaber GOWIL ; Amany Saleh ELYAMANY ; Mohamed ESHAFEI
Korean Journal of Clinical Oncology 2016;12(1):32-40
PURPOSE: We evaluated oral metronomic capecitabine (MC) compared to intravenous doxorubicin in patients with advanced or metastatic hepatocellular carcinoma (HCC).METHODS: From January 2013 to December 2015, patients with Child-Pugh class A or early B were randomized either to MC group (500 mg twice daily continuously) or doxorubicin group (60 mg/m² every 21 days).RESULTS: Forty patients were included in each group. The baseline clinical characteristics of the enrolled patients were well balanced between the two groups. No complete response (CR) was reported in either group. In MC group, 2 patients (5%) had partial response (PR), 25 patients (62.5%) stable disease (SD) and 27 patients (67.5%) had disease control. In doxorubicin group, 4 patients (10%) achieved PR, 24 patients (60%) SD and 28 patients (70%) had disease control. The 6 months overall survival (OS) was 77.5% for MC and 75% for doxorubicin. The one year OS was 47.5% for MC and 42.5% for doxorubicin (P=0.521). The median OS survival was 10.2 months for MC and 9.6 months for doxorubicin (95% confidence interval, 3.2–6.5). The 6 month progression-free survival (PFS) was 45% for MC and 50% for doxorubicin. The one year PFS was 12.5% for MC and 7.5% for doxorubicin (P=0.289). The median time to progression was 3.4 months for MC and 3.1 months for doxorubicin. On multivariate analysis no significant impact for tumor stage, previous transhepatic arterial chemoembolization, portal vein thrombosis or median baseline alpha fetoprotein on OS.CONCLUSION: MC showed response rate and survival outcome comparable to doxorubicin in advanced HCC but with a more favorable toxicity profile.
alpha-Fetoproteins
;
Capecitabine
;
Carcinoma, Hepatocellular
;
Disease-Free Survival
;
Doxorubicin
;
Humans
;
Multivariate Analysis
;
Venous Thrombosis
7.A case of focal nodular hyperplasia with growth progression during pregnancy.
Min Ji KIM ; Sang Young HAN ; Yang Hyun BAEK ; Sung Wook LEE ; Hee Jin KWON
Clinical and Molecular Hepatology 2014;20(4):392-397
Focal nodular hyperplasia (FNH) is the second most common benign solid tumor of the liver and is usually found in young females. In FNH, spontaneous bleeding or rupture rarely occurs and malignant transformation is unlikely. The etiology of FNH is unclear, but because of female predominance and young age at onset, it seems that female hormone has an important role for the development of FNH. Although the development and the complications of hepatocellular adenomas have been related to the use of oral contraceptives and pregnancy, the influence of oral contraceptives and pregnancy on the growth and complications of FNH is controversial. Most FNH are stable in size and rarely complicated during pregnancy. We describe here a case of FNH with growth progression during pregnancy in a 27-year-old female. Her course of pregnancy and delivery was uneventful. Two months after delivery, the size of FNH was decreased.
Adult
;
Female
;
Focal Nodular Hyperplasia/*diagnosis/radiography/ultrasonography
;
Humans
;
Liver/pathology/radiography
;
Pregnancy
;
Tomography, X-Ray Computed
;
alpha-Fetoproteins/analysis
8.Outcome and Risk Factor of Early Recurrence of Hepatocellular Carcinoma after Liver Transplantation and Effect of Pre-transplant Transarterial chemoembolization on Post-transplant Outcome.
Chae Young LEE ; Dong Goo KIM ; Say June KIM ; In Sung MOON ; Myung Duk LEE
Journal of the Korean Surgical Society 2007;72(5):379-386
PURPOSE: The aims of this study were to find the risk factor and outcomes of patients with an early recurrence (ER) of a hepatocellular carcinoma (HCC) after liver transplantation (LT) and the actual impact of transarterial chemoembolization (TACE) before LT for a HCC on patient survival and HCC recurrence. METHODS: Ninety-eight cases of adult LT, performed between September 1995 and January 2006, were evaluated. The risk factors and prognosis of patient with a HCC after transplantation for an ER, defined as a recurrence within 6 months of transplantation, and the effects of Pre-LT TACE on the disease-free and overall survival rates, as well as the patterns of recurrence after LT, were studied. RESULTS: A total of 18 patients (18.4%) experienced a HCC recurrence after LT; 10 and 8 patients had early and late recurrences, respectively. From a univariate analysis, the serum alpha-fetoprotein (P=0.003), tumor size (P=0.003), serosa invasion (P=0.000), tumor grade (P=0.011) and vascular invasion (P=0.014) were statistically significant risk factors for an ER. From a multivariate analysis, the presence of serosa invasion of a HCC was the only independent risk factor for an ER (P=0.009; OR=9.407: 95% CI, 1.764~50.164). There was no difference in the disease free sur-vival and overall survival rates between the TACE and without TACE groups, but the extrahepatic recurrence rate was higher in the TACE than without TACE group. CONCLUSION: Serosa invasion by a HCC is independently associated with an ER of HCC after LT. Pre-LT TACE does not influence the disease-free and overall survivals after LT for a HCC.
Adult
;
alpha-Fetoproteins
;
Carcinoma, Hepatocellular*
;
Humans
;
Liver Transplantation*
;
Liver*
;
Multivariate Analysis
;
Prognosis
;
Recurrence*
;
Risk Factors*
;
Serous Membrane
;
Survival Rate
9.Cost-Effectiveness of Liver Cancer Screening in Adults at High Risk for Liver Cancer in the Republic of Korea.
Young Hwa LEE ; Kui Son CHOI ; Jae Kwan JUN ; Mina SUH ; Hoo Yeon LEE ; Youn Nam KIM ; Chung Mo NAM ; Eun Cheol PARK ; Woo Hyun CHO
Cancer Research and Treatment 2014;46(3):223-233
PURPOSE: This study was conducted in order to determine the most cost-effective strategy, in terms of interval and age range, for liver cancer screening in the high-risk population of Korea. MATERIALS AND METHODS: A stochastic model was used to simulate the cost-effectiveness of liver cancer screening by combined ultrasonography and alpha-fetoprotein testing when varying both screening intervals and age ranges. The effectiveness of these screening strategies in the high-risk population was defined as the probability of detecting preclinical liver cancer, and cost was based on the direct cost of the screening and confirmative tests. Optimal cost-effectiveness was determined using the incremental cost-effectiveness ratio. RESULTS: Among the 36 alternative strategies, one-year or two-year interval screening for men aged between 50 and 80 years, six-month or one-year interval screening for men aged between 40 and 80 years, and six-month interval screening for men aged between 30 and 80 years were identified as non-dominated strategies. For women, identified non-dominated strategies were: one-year interval screening between age 50 and 65 years, one-year or six-month interval screening between age 50 and 80 years, six-month interval screening between age 40 and 80 years, and six-month interval screening between age 30 and 80 years. CONCLUSION: In Korea, a one-year screening interval for men aged 50 to 80 years would be marginally cost-effective. Further studies should be conducted in order to evaluate effectiveness of liver cancer screening, and compare the cost effectiveness of different liver cancer screening programs with a final outcome indicator such as quality-adjusted life-years or disability-adjusted life-years.
Adult*
;
alpha-Fetoproteins
;
Cost-Benefit Analysis
;
Female
;
Humans
;
Korea
;
Liver Neoplasms*
;
Male
;
Mass Screening*
;
Republic of Korea*
;
Ultrasonography
10.Uterine artery Doppler velocimetry in the prediction of adverse obstetric outcomes in unexplained MSAFP elevations.
Jae Eun CHUNG ; Jae Sung CHO ; Sung Shik HAN ; Yong Won PARK ; Jae Wook KIM
Yonsei Medical Journal 2000;41(1):17-21
Unexplained maternal serum-fetoprotein (MSAFP) elevation has been known to be associated with adverse obstetric outcomes, however it is not sufficiently useful as a screening test. This study was undertaken to determine whether uterine artery Doppler velocimetry could define a subset of patients with an elevated MSAFP level in whom complications of pregnancy might develop. The subjects included 179 women between 26 and 28 weeks' gestation with MSAFP > or = 2.5 multiples of the median, in whom either the presence of an early diastolic notch or a resistance index 0.6 was considered as an abnormal Doppler velocimetry finding. Those subjects who displayed abnormal Doppler velocimetry findings showed an increased incidence of preeclampsia, preterm birth, IUGR, and IUFD compared to those subjects with only elevated MSAFP (p < 0.05). No differences were observed in the incidence of LBW. Positive predictive values of adverse obstetric outcomes were significantly higher in the group having both elevated MSAFP and abnormal Doppler velocimetry compared to the group with only elevated MSAFP (p < 0.05). Uterine artery Doppler velocimetry in the second trimester can improve the value of unexplained MSAFP elevation in the prediction of adverse obstetric outcomes.
Adult
;
Arteries/ultrasonography
;
Female
;
Forecasting
;
Human
;
Incidence
;
Pregnancy/blood*
;
Pregnancy Complications*/epidemiology
;
Uterus/ultrasonography*
;
Uterus/blood supply*
;
alpha-Fetoproteins/analysis*